Difference between revisions of "BRAF mutation"

From Libre Pathology
Jump to navigation Jump to search
 
Line 2: Line 2:


==General==
==General==
*Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal  | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref>
*Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal  | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref>


===Prevalence===
===Prevalence===

Latest revision as of 18:20, 23 January 2019

BRAF mutation is a common genetic change in cancer. The most common BRAF mutation is the so-called BRAF V600E mutation.

General

  • Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.[1]

Prevalence

BRAF mutations by tumour type:[1]

  • BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
  • BRAF mutations in ~ 10% of colorectal tumours.
    • Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
  • BRAF mutations in ~45-50% of papillary thyroid carcinoma.
  • BRAF mutations in ~3% of lung adenocarcinomas.

See also

References

  1. 1.0 1.1 Cheng, L.; Lopez-Beltran, A.; Massari, F.; MacLennan, GT.; Montironi, R. (01 2018). "Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.". Mod Pathol 31 (1): 24-38. doi:10.1038/modpathol.2017.104. PMID 29148538.